Filing Flows › Companies › Aligos Therapeutics › Timeline
Aligos Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−42.7% to $4.07
Aligos Therapeutics (ALGS) stock fell 43% over the last 252 sessions, to $4.07. On the way it reported 0 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside), and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Sep 15, 2026 | 8-K | Material definitive agreement | +1.2% (+1.6% vs SPY) | +12.9% (+10.6% vs SPY) | +4.7% (+2.8% vs SPY) |
| Jun 26, 2026 | 8-K | Directors and officers: departures, appointments, pay | −2.6% (−4.2% vs SPY) | +4.9% (+1.9% vs SPY) | −27.1% (−28.7% vs SPY) |
| Apr 21, 2026 | 8-K | Material definitive agreement | −0.8% (−1.8% vs SPY) | −4.2% (−5.3% vs SPY) | −15.8% (−21.0% vs SPY) |
| Feb 4, 2026 | 8-K | Directors and officers: departures, appointments, pay | −8.6% (−7.3% vs SPY) | +5.4% (+4.5% vs SPY) | −1.3% (+0.8% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Aligos Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.